Chat with us, powered by LiveChat
  • Get inspired by peer-reviewed publications of our scientists, partners, and customers around the globe.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

News

MIMETAS in the global news. Read more about our latest research, developments, collaborations, and product launches.
Sign up for our newsletter to stay up to date.

MIMETAS participates in GRIPonMASH initiative to improve prevention and care of Metabolic dysfunction-Associated Steatohepatitis (MASH)

Utrecht, February 5, 2024 – MIMETAS, a global leader in organ-on-chip-based disease models, is playing a pivotal role in the GRIPonMASH initiative, a newly established consortium dedicated to transforming the detection and treatment of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD).

Read more
MIMETAS and Yamaha Motor Sign Joint Marketing Agreement to Advance Automated Human Disease Model Applications for Drug Development

Leiden, 29 November 2023 — MIMETAS, a leader in human 3D disease modeling, and Yamaha Motor Co., Ltd., a developer of the CELL HANDLERTM, announce a strategic joint marketing partnership aimed at advancing therapeutic development using human-relevant models throughout the early drug development pipeline.

Read more
Microfluidic Models of the Neurovascular Unit: A Translational View

Leiden, November 27, 2023 Researchers from MIMETAS and Amsterdam UMC have published an article on advancements in microfluidic in vitro modeling of the blood-brain barrier (BBB) and neurovascular unit (NVU). Their work was published in Fluids and Barriers of the CNS.

Read more
MIMETAS Co-CEO, Paul Vulto, nominated as new Netherlands Academy of Engineering Fellow

The Hague, November 2, 2023 – Netherlands Academy of Engineering nominates MIMETAS CEO, Paul Vulto as a new Fellow, alongside 61 others, to actively contribute to their mission. This nomination emphasizes the crucial role of innovative technological solutions in addressing pressing societal challenges and sustainable change.

Read more
Human BBB-on-a-chip reveals barrier disruption, endothelial inflammation, and T cell migration under neuroinflammatory conditions

Leiden, September 14, 2023 – MIMETAS Scientists established a high-throughput human BBB-on-a-chip to study neuroinflammation and transendothelial migration.

Read more
The first large-scale phenotypic screen using Organ-on-a-Chip: a 1537 kinase inhibitor library screen on a 3D angiogenesis assay

Leiden, August 1, 2023 – MIMETAS researchers report the first large-scale phenotypic screen utilizing Organ-on-a-Chip (OoC) technology. This groundbreaking study was published in the Journal of Angiogenesis.

Read more
MIMETAS and Dundee placenta model could transform pregnancy healthcare

Leiden July 14, 2023 - A placenta on a chip developed at the University of Dundee has the potential to transform research into life-threatening conditions in pregnancy.

Read more
The National Growth Fund Reserves 125 million euros for the Transition to Animal-Free Innovation

Utrecht, 30 June 2023 - The Center for Animal-Free Biomedical Translation (CPBT) is planning to accelerate the transition to animal-free biomedical innovations. This should offer economic and social benefits: improved medicines and fewer animal tests. MIMETAS (Leiden, The Netherlands), the renowned leader in human tissue and disease modeling using organ-on-a-chip technologies, proudly announces its partnership in the CPBT consortium, focusing on ALS, lower back pain, and protein transition & food allergy. This collaboration marks a significant step towards advancing pharmaceutical, chemical, and food component development while minimizing reliance on animal testing.

 

Read more
MIMETAS and Astellas Expand Partnership to Include Automation and Application Support

Leiden June 20, 2023 – MIMETAS, a global leader in human disease modeling announces that it has expanded its ongoing partnership with Astellas, a global pharmaceutical company, to include automation and application support.

Read more
The tumor stroma influences immune cell distribution and recruitment in a PDAC-on-a-chip model

Leiden, May 10, 2023 – MIMETAS scientists develop and characterize a pancreatic ductal adenocarcinoma (PDAC) model and applied it to study the role of the endothelium and the stroma in immune cell migration.

Read more
Healthy and diseased placental barrier on-a-chip models suitable for standardized studies

Leiden, May 5, 2023MIMETAS researchers develop an in vitro model of the placental barrier, which could aid in understanding preeclampsia (PE) and other placental pathologies associated with hypoxia/ischemia.

Read more
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-oncology

Leiden, March 28, 2023 – MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company.

Read more
MIMETAS Achieves Important Milestones in Partnership with Roche

Leiden, March 22, 2023 – MIMETAS has achieved major milestones in its partnership with Roche, developing models for Inflammatory Bowel Disease (IBD) and Hepatitis B Virus Infections (HBV).

Read more
MIMETAS Launches Ready-to-Use 3D Adult Stem Cell Organoid Tubules

Leiden, March 7, 2023 - MIMETAS announces that it has launched its Adult Stem Cell-derived Colon and Kidney tubular organoids in an assay ready format.

Read more
Gut-on-a-Chip Models: Current and Future Perspectives for Host–Microbial Interactions Research

Leiden, February 24, 2023 – MIMETAS scientists shed light on the potential role of gut-on-a-chip models for studying host-microbial interactions in the context of intestinal physiology.

Read more
A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment

Leiden, February 3, 2023 – MIMETAS scientists established a 3D Pancreatic Ductal Adenocarcinoma (PDAC) model, enabling the study of cancer treatment response in PDAC organoids.

Read more
Vascular inflammation on a chip: A scalable platform for trans-endothelial electrical resistance and immune cell migration
Leiden, January 30, 2023 – MIMETAS scientists develop a vasculature inflammation model using a scalable and automation-compatible platform and present a method to study vascular barrier integrity in real-time.
Read more
A 3D Perfusable Platform for In Vitro Culture of Patient Derived Xenografts
Leiden, January 9, 2023 Scientists from MIMETAS and the University of Texas Health Center develop a model system that supports the culture of clinically relevant PDX cells that recapitulate aspects of the prostate cancer (PCa) tumor microenvironment (TME).
Read more
MIMETAS elected most innovative company of the Netherlands

Leiden, November 2, 2022 MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position.

Read more
High-throughput 3D microvessel-on-a-chip model to study defective angiogenesis in systemic sclerosis
Leiden, October 10, 2022 Scientists from MIMETAS and Galapagos used a high-throughput 3D microvessel-on-a-chip on the OrganoPlate platform to study angiogenesis in the context of systemic sclerosis. This article has just been published in Scientific Reports.
Read more
A versatile multiplexed assay to quantify intracellular ROS and cell viability in 3D on-a-chip models
Leiden, September 30, 2022 – Scientists from MIMETAS develop a multiplexed assay to quantify reactive oxidative species (ROS) and cell viability in organ-on-a-chip models. This article was published in the Journal of Redox Biology.
Read more
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors

LEIDEN, September 8, 2022 – MIMETAS, a global leader in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel as Chair of its Board of Directors.

Read more
In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed
Leiden, June 16, 2022 Scientists from MIMETAS introduce a platform for routine grafting of liver and other tissues on an in vitro grown microvascular bed. This article has just been published in Angiogenesis.
Read more
MIMETAS Expands Adult Stem Cell Organoid License to All Organs
Leiden, May 3, 2022 – MIMETAS announces today that it has expanded its license to the HUB Organoid Technology to include all organs. The license covers organoid technology developed by Professor Hans Clevers, a pioneer in adult stem cells.
Read more
MIMETAS participates in €325 million Oncode Accelerator initiative to accelerate and improve oncology drug development
Leiden, April 14, 2022 MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund.
Read more
MIMETAS attends AACR 2022 Conference in New Orleans
New Orleans, April 8-13, 2022 – MIMETAS recently attended the AACR Annual Meeting in person. The AACR Annual Meeting covers the latest discoveries across the spectrum of cancer research.
Read more
Modelling and prevention of acute kidney injury
Leiden, February 24, 2022 – Scientists from MIMETAS and Astellas introduce a combined human renal proximal tubule/blood vessel-on-a-chip model in the OrganoPlate® 3-lane 40 to study acute kidney injury caused by renal ischemia/reperfusion injury. This article has just been published in Kidney360.
Read more
Phase 2 funding of £1 million awarded by CRACK IT Challenges to develop TDAR-on-a-chip
Leiden, February 22, 2022 MIMETAS has been awarded by NC3Rs' CRACK IT Challenges competition with Phase 2 funding for the development of a human in vitro T-cell dependent antibody response (TDAR) assay.
Read more
MIMETAS in TEDx: 'Why Organs-on-Chips raise the odds in drug development'

Leiden, February, 2022 – TEDxBoerhaavedistrictStudio guides us through a virtual ‘Walk in the Park’ with inspiring TEDx speakers from the Boerhaavedistrict in Leiden, The Netherlands. This month, Jos Joore (MIMETAS’ CEO) explains why the development of pharmaceuticals is a hugely expensive and uncertain process and offers a possible solution for more efficient drug development.

Read more
MIMETAS attends SLAS 2022 Conference in Boston, Massachusetts
Leiden, February 14, 2022 – MIMETAS has just attended the annual SLAS International Conference and Exhibition in person, which took place on February 5-9, 2022, in Boston, Massachusetts. This flagship conference connects great minds in life sciences and technology with each other and with the innovation, technology, and automation needed to transform research each year.
Read more
Organ-on-a-Chip technology for in vitro grafting and vascularisation of 3D tissues
Oegstgeest, January 3, 2022 – In 2019, MIMETAS was granted two-year funding and support by the SME instrument for the project 'OrganoPlate Graft'. The project resulted in the development of the first OrganoReady® Vascular bed: a ready-to-use OrganoPlate® Graft with pregrown vascular beds.
Read more
Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening
Leiden, December 29, 2021 Scientists from MIMETAS published an article on using microfluidic platforms for modelling and studying Pancreatic Ductal Adenocarcinoma and as translational models for drug screening. Their work was published in Frontiers in Cell and Developmental Biology.
Read more
Modeling ischemic stroke in a triculture neurovascular unit on-a-chip
Leiden, December 15, 2021 – Scientists from MIMETAS introduce a new neurovascular unit on-a-chip model to study ischemic events in the human brain. This research has just been published in Fluids and Barriers of the CNS.
Read more
A novel in vitro membrane permeability methodology using three-dimensional Caco-2 tubules in a microphysiological system
Leiden, November 23, 2021 – Scientists from MIMETAS and Astellas introduce a new method to study in vitro drug permeability based on 3D Caco-2 tubules cultured in the OrganoPlate® 3 lane-40. This article has just been published in the Journal of Pharmaceutical Sciences.
Read more
Adoption of organ-on-chip platforms by the pharmaceutical industry
Leiden, October 13, 2021 – Our CEOs Paul Vulto and Jos Joore published a correspondence article about the adoption of organ-on-chip platforms by the pharmaceutical industry. This article has been published in Nature Reviews – Drug Discovery.
Read more
Intestinal Epithelium Tubules on a Chip
Leiden, September 15, 2021 – Scientists from MIMETAS introduce a method to culture intestinal epithelium tubules-on-a-chip in the OrganoPlate® 3 lane 40. This book chapter has just been published in Methods in Molecular Biology – Organ-on-a-chip Methods and Protocols.
Read more
A Microfluidic 3D Endothelium-on-a-Chip Model to Study Transendothelial Migration of T Cells in Health and Disease
Leiden, August 2, 2021 - Scientists from MIMETAS and Merck introduce an assay to study 3D T cell dynamics under flow and in real-time using a high-throughput, artificial membrane-free microfluidic platform. The research has just been published in the International Journal of Molecular Sciences.
Read more
MIMETAS and Roche enter into a collaboration to develop human disease models for drug development
Leiden, July 6, 2021 - MIMETAS, a leader in organ-on-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced today that they have entered into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV).
Read more
Long-Lived Human Lymphatic Endothelial Cells to Study Lymphatic Biology and Lymphatic vessel/Tumor Coculture in a 3D Microfluidic Model
Leiden, June 29, 2021 - Scientists from MIMETAS and the UMC Utrecht introduce a new organ-on-a-chip lymphatic vessel model together with a novel long-lived lymphatic cell line to study the lymphatic system in health and disease. This research has been published in ACS Biomaterials Science & Engineering.
Read more
MIMETAS wins Deshima award for Dutch-Japanese business relations
Leiden & Tokyo, June 7, 2021 - MIMETAS has been awarded the ‘Deshima Business Award” in the category ‘Newly Established’ by the NCCJ, and the Embassy of the Kingdom of the Netherlands.
Read more
MIMETAS opens Phenotypic Screening Center
Leiden, May 27, 2021 - MIMETAS, the global leader in human-relevant organ-on-a-chip models, has just opened their Phenotypic Screening Center. The center facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the human physiological relevance of cultured tissues by utilizing microfluidic techniques.
Read more
MIMETAS appoints Patrice Denèfle as Scientific Advisor
Leiden, April 22, 2021 - MIMETAS, the global leader in organ-on-a-chip-based disease modeling, is happy to announce the appointment of Patrice Denèfle as their Scientific Advisor. Patrice brings in longstanding scientific expertise and an extensive network in the pharmaceutical industry. His involvement will support the therapeutic research strategy and spark new collaborations with leading pharmaceutical companies based on MIMETAS’ phenotypic modeling and screening capabilities.
Read more
TEER measurements on perfused membrane-free epithelia
Leiden, April 16, 2021 - Scientists from MIMETAS, Sciospec and Leiden University introduce an instrument that measures TransEpithelial Electrical Resistance (TEER) of perfused epithelial tubes in the microfluidic OrganoPlate® platform. The research is recently published in the Journal Lab on a Chip.
Read more
Robust and versatile renal tubule-on-a-chip for nephrotoxicity assessment
March 31, 2021 – MIMETAS, Roche Innovation Center, Pfizer, GlaxoSmithKline (GSK), Utrecht Institute for Pharmaceutical Sciences, University of Applied Sciences Northwestern Switzerland, and the Swiss Centre for Applied Human Toxicology, developed a high throughput, 3D microfluidic platform (Nephroscreen) to detect drug-induced nephrotoxicity.
Read more
£900k awarded by CRACK IT Challenges to develop TDAR-on-a-chip
February 9, 2021 – MIMETAS has been awarded by NC3Rs' CRACK IT Challenges competition with Phase 1 funding for the development of a human in vitro T-cell dependent antibody response (TDAR) assay.
Read more
3D-cember 2020: videos of talks now on-demand

December 10, 2020 – To put new developments in 3D tissue biology in the limelight, MIMETAS organizes 3D-cember every 3rd of December. Videos of the 2020 live-streamed edition are now available on-demand.

Read more
MIMETAS launches assay ready product line for Organ-on-a-Chip
March 3, 2020 Innovative in vitro models ready-to-use for safety, ADME, and toxicology studies in drug development and food & nutrition research.
Read more
Snake Venom Gland Organoids

January 23, 2020 – The Hubrecht institute and MIMETAS investigated if venom molecules produced by snake venom gland organoids also function as actual venom using the OrganoPlate® platform.

Read more
MIMETAS and Hubrecht Organoid Technology to develop and market Organoids-on-a-Chip
October 1, 2019 – MIMETAS and Hubrecht Organoid Technology (HUB) entered into a strategic collaboration to market organoid models on a chip.
Read more
Adult Stem Cell-Derived Kidney-on-a-Chip in Nature Biotechnology

March 5, 2019 – Leading stem cell research group and global leader in organ-on-a-chip technology develop stem cell-derived kidney tubules in microfluidic chips.

Read more
MIMETAS Secures 20 Million Dollar Series B Financing

April 11, 2018 – Global leader in organ-on-a-chip technology backed by international syndicate for worldwide commercial expansion and new product development.

Read more
MIMETAS in consortium to develop in vitro placenta models
March 17, 2018 – MIMETAS in a consortium to develop in vitro placenta models.
Read more
MIMETAS partner in €4.5mn EU Interreg project BIOMAT
January 1, 2018 – MIMETAS is partner of the Interreg project 'Biomat' aiming to develop a platform for high-throughput testing of biomaterials in a physiologically relevant environment on-a-chip.
Read more
MIMETAS raises 5.2 million dollar for organ-on-a-chip
October 8, 2014 – MIMETAS B.V. announces that it has raised 5.2 million dollar to fund its expansion as a global leader in organ-on-a-chip technology.
Read more

Cookies

‘May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy

Accept all
Accept selected
Decline all